Novartis partners with Conatus on new oral treatments for chronic liver diseases
The companies signed an exclusive option, collaboration and license agreement for the worldwide development and commercialization of Conatus’ emricasan, an investigational oral, pan-caspase inhibitor intended to treat non-alcoholic